Author

Navit Naveh

Observed names: N. Naveh, Naveh, Navit

Institutions: Jazz Pharmaceuticals (United States), Jazz Pharmaceuticals (Ireland)

Observed institutions: Jazz Pharmaceuticals (United States), Jazz Pharmaceuticals (Ireland)

OpenAlex ID: A5089007034

Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer

2023 · Raj Hanvesakul, Badri Rengarajan, et al. · Journal of Comparative Effectiveness Research · 10

1539P Real-world (RW) outcomes of second-line (2L) small cell lung cancer (SCLC) patients treated with lurbinectedin

2022 · A. Estrin, X. Wang, et al. · Annals of Oncology · 4

P1.13A.10 Efficacy and Safety of Lurbinectedin for Small Cell Lung Cancer in a Real-World Setting: Jazz EMERGE 402 Study

2024 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology · 2

HSD69 Patient Characteristics and Treatment Patterns in Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

2025 · Wade Iams, Tavvy Miller, et al. · Value in Health · 1

Real-world safety and healthcare resource utilization (HCRU) of lurbinectedin (lurbi) in patients (pts) with small cell lung cancer (SCLC): Jazz EMERGE 402 updated analysis.

2024 · Firas Benyamine Badin, Philip Edward Lammers, et al. · Journal of Clinical Oncology · 1

P2.17-07 Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis

2023 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology · 1

PP01.76 Lurbinectedin vs an External Control arm in Patients with Small Cell Lung Cancer

2023 · A. Kishor Ganti, P. Prince, et al. · Journal of Thoracic Oncology · 1

Efficacy of lurbinectedin in a clinical trial versus other standard of care in a real-world comparator arm in relapsed/refractory small cell lung cancer patients.

2022 · Apar Kishor Ganti, Patricia Prince, et al. · Journal of Clinical Oncology · 1

Real-world (RW) effectiveness and safety of lurbinectedin (lurbi) for previously treated extensive-stage small cell lung cancer (ES-SCLC): Final primary and subgroup analysis results of Jazz EMERGE 402.

2026 · Firas Benyamine Badin, Phil Lammers, et al. · Journal of Clinical Oncology

Comparison of real-world overall survival between atezolizumab- and durvalumab-containing first-line induction and maintenance regimens in extensive-stage small cell lung cancer.

2026 · Apar Kishor Ganti, Jeremy Snider, et al. · Journal of Clinical Oncology

PP01.138: Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402

2026 · Firas Badin, Philip Lammers, et al. · Journal of Thoracic Oncology

429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402

2026 · B. Halmos, P. Lammers, et al. · ESMO Open

P3.13.31 Real-World Effectiveness and Safety of Lurbinectedin for Small Cell Lung Cancer (SCLC): Updates From Jazz EMERGE 402

2025 · B. Halmos, P. Lammers, et al. · Journal of Thoracic Oncology

PP01.119 Real-World Use of Lurbinectedin in Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Updated Analysis

2024 · Balazs Halmos, Philip Lammers, et al. · Journal of Thoracic Oncology

PP01.77 EMERGE 402: Real-world Characteristics and Safety of Lurbinectedin in Small-cell Lung Cancer (SCLC)

2023 · D. Schreeder, F. Badin, et al. · Journal of Thoracic Oncology

P2.10-02 EMERGE 402: Preliminary Real-world Characteristics and Safety of Lurbinectedin in Patients With Small-cell Lung Cancer

2022 · P. Bushunow, S. Dakhil, et al. · Journal of Thoracic Oncology

Works count: 17

Citation count: 21

H-index: 2

I10-index: 1